0
0
Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
The Business Research Company’s Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON, UK, April 6, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $2.21 billion in 2020 to $3.02 billion in 2021 at a compound annual growth rate (CAGR) of 36.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The infliximab, etanercept, and adalimumab biosimilars market size is expected to reach $12.2 billion in 2025 at a CAGR of 42%.
The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules such as Humira, Remicade and Enbrel, respectively. Biosimilars are pharmaceuticals that are manufactured using cell lines and offer no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired. The global biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer.
Read More On The Global Adalimumab, Infliximab And Etanercept Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-global-market-report-2020-30-covid-19-growth-and-change
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented by product into adalimumab biosimilars (exemptia, mabura, hyrimoz, hadlima, abrilada, others), infliximab biosimilars (inflectra, renflexis, ixifi, avsola), cipleumab (erelzi, eticovo). The adalimumab, infliximab and etanercept biosimilars market is also segmented by application into Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, others, and by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.
Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, and Mylan.
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides adalimumab, infliximab and etanercept biosimilars market overview, forecast adalimumab, infliximab and etanercept biosimilars market size and growth for the whole market, adalimumab, infliximab and etanercept biosimilars market segments, and geographies, adalimumab, infliximab and etanercept biosimilars market trends, adalimumab, infliximab and etanercept biosimilars market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Adalimumab, Infliximab And Etanercept Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
Here Is A List Of Similar Reports By The Business Research Company:
Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/biosimilars-market-global-report
Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market
Arthritis Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change
Psoriatic Arthritis Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatment-global-market-report-2020-30-covid-19-growth-and-change
Autoimmune Disease Diagnosis Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-market-global-report-2020-30-covid-19-growth-and-change
Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn
Average Rating